FORMULATION AND COMPARATIVE EVALUATION OF VARIOUS NATURAL POLYMER-BASED SOLID DISPERSIONS OF NAPROXEN FOR ENHANCED SOLUBILITY AND DISSOLUTION

Authors

  • Mukta Bhati M.pharm , Jaipur College of Pharmacy Author
  • Dr. Mayank Bansal Author

DOI:

https://doi.org/10.5281/zenodo.22854998

Keywords:

Keywords: Naproxen; Solid dispersion; Natural polymer; Guar gum; Xanthan gum; Gum acacia; Solubility enhancement; Dissolution rate; BCS Class II; Amorphization.

Abstract

Background: Naproxen, a propionic-acid-derived non-steroidal anti-inflammatory drug (NSAID), is classified under Biopharmaceutics Classification System (BCS) Class II, meaning it is highly permeable across the intestinal membrane but poorly soluble in aqueous media, so its rate-limiting step for oral absorption is dissolution rather than membrane transport. This solubility bottleneck contributes to slow and variable release from conventional dosage forms, which in clinical practice can encourage higher or more frequent dosing and, in turn, a greater burden of NSAID-related gastrointestinal adverse effects.

Objective: The present investigation was undertaken to formulate solid dispersions of naproxen using three hydrophilic natural polysaccharide gums — guar gum (GG), xanthan gum (XG) and gum acacia (GA) — and to comparatively evaluate their capacity to enhance aqueous solubility and in-vitro dissolution relative to one another and to the unprocessed drug.

Methods: Twenty-seven formulation batches were generated by fully crossing the three carriers, three preparation techniques (solvent evaporation, fusion/melt, and kneading) and three drug-to-polymer ratios (1:1, 1:2 and 1:3 w/w). Pre-formulation studies — organoleptic evaluation, melting-point verification, equilibrium solubility profiling and FTIR-based drug–polymer compatibility screening — preceded formulation. Every batch was assessed for drug content, equilibrium solubility (in water and pH 6.8 phosphate buffer) and USP Apparatus II dissolution behaviour; the best-performing batch was further characterised in-house by FTIR and differential scanning calorimetry (DSC), compared against powder X-ray diffraction (XRD) data reported in the literature for analogous systems, and subjected to a 90-day accelerated stability study conducted in line with ICH Q1A(R2).

Results: Every natural-gum carrier improved both solubility and dissolution relative to pure naproxen (p < 0.001). The guar-gum system prepared by solvent evaporation at a 1:3 ratio (GG-SE3) was clearly the most effective, releasing 94.82 ± 3.1% of the drug within 60 minutes against only 28.6 ± 1.8% for the unprocessed drug, together with a 4.6-fold increase in phosphate-buffer solubility. DSC (this study) and XRD (compared from the literature for analogous systems) confirmed that this improvement coincided with a substantial reduction in naproxen crystallinity, consistent with conversion of the drug to a largely amorphous, molecularly dispersed state within the guar-gum matrix. The optimised batch retained the great majority of its performance across 90 days of accelerated storage (40 °C ± 2 °C / 75% RH ± 5%), with no statistically significant change in drug content, dissolution or solubility (p > 0.05).

Conclusion: Natural polysaccharide gums, and guar gum in particular, represent an inexpensive, biocompatible and technically effective platform for improving the dissolution behaviour — and, by extension, the likely oral bioavailability — of naproxen and potentially other BCS Class II NSAIDs.

References

1. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413-420.

2. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods. 2000;44(1):235-249.

3. Kalepu S, Nekkanti V. Insoluble drug delivery strategies: review of recent advances and business prospects. Acta Pharm Sin B. 2015;5(5):442-453.

4. Pouton CW. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci. 2006;29(3-4):278-287.

5. Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, Conner DP, et al. Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm Res. 2002;19(7):921-925.

6. Avdeef A. Solubility of sparingly-soluble ionizable drugs. Adv Drug Deliv Rev. 2007;59(7):568-590.

7. World Health Organization. Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms. WHO Technical Report Series No. 937. Geneva: WHO; 2006.

8. Savjani KT, Gajjar AK, Savjani JK. Drug solubility: importance and enhancement techniques. ISRN Pharm. 2012;2012:195727.

9. Vasconcelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today. 2007;12(23-24):1068-1075.

10. Sostres C, Gargallo CJ, Arroyo MT, Lanas A. Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper and lower gastrointestinal tract. Best Pract Res Clin Gastroenterol. 2010;24(2):121-132.

11. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. J Am Coll Cardiol. 2008;52(18):1502-1517.

12. Patel T, Bhatt P, Bhatt N. Naproxen: a review of its physicochemical properties, pharmacology and formulation considerations. Int J Pharm Sci Rev Res. 2020;63(1):118-126.

13. Müller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future. Adv Drug Deliv Rev. 2001;47(1):3-19.

14. Stahl PH, Wermuth CG, editors. Handbook of Pharmaceutical Salts: Properties, Selection, and Use. 2nd ed. Weinheim: Wiley-VCH; 2011.

15. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins: basic science and product development. J Pharm Pharmacol. 2010;62(11):1607-1621.

16. Yalkowsky SH. Solubility and Solubilization in Aqueous Media. New York: Oxford University Press; 1999.

17. Sekiguchi K, Obi N. Studies on absorption of eutectic mixture. I. A comparison of the behavior of eutectic mixture of sulfathiazole and that of ordinary sulfathiazole in man. Chem Pharm Bull (Tokyo). 1961;9(11):866-872.

18. Chiou WL, Riegelman S. Pharmaceutical applications of solid dispersion systems. J Pharm Sci. 1971;60(9):1281-1302.

19. Dhirendra K, Lewis S, Udupa N, Atin K. Solid dispersions: a review. Pak J Pharm Sci. 2009;22(2):234-246.

20. Vo CL, Park C, Lee BJ. Current trends and future perspectives of solid dispersions containing poorly water-soluble drugs. Eur J Pharm Biopharm. 2013;85(3 Pt B):799-813.

21. Yu L. Amorphous pharmaceutical solids: preparation, characterization and stabilization. Adv Drug Deliv Rev. 2001;48(1):27-42.

22. Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm. 2000;50(1):47-60.

23. Hasnain MS, Nayak AK. Natural polysaccharides and their derivatives as pharmaceutical excipients. In: Nayak AK, Hasnain MS, editors. Natural Polysaccharides in Drug Delivery and Biomedical Applications. London: Academic Press; 2019. p. 1-17.

24. Bhosale RR, Osmani RA, Moin A. Natural gums and mucilages: a review on multifaceted excipients in pharmaceutical science and research. Int J Pharmacogn Phytochem Res. 2014;15(4):901-912.

25. Szejtli J. Cyclodextrin Technology. Dordrecht: Kluwer Academic Publishers; 1988.

26. Attia MA. Pharmaceutical properties of naproxen from its complexes with β-cyclodextrin. Drug Dev Ind Pharm. 1992;18(14):1503-1510.

27. Tubic-Grozdanis M, Bolger MB, Langguth P. Application of gastrointestinal simulation for extensions for BCS waiver for highly permeable compounds. AAPS J. 2008;10(1):213-226.

28. Khadka P, Ro J, Kim H, Kim I, Kim JT, Kim H, et al. Pharmaceutical particle technologies: an approach to improve drug solubility, dissolution and bioavailability. Asian J Pharm Sci. 2014;9(6):304-316.

29. Sharma A, Gupta A, Rath G. Solid dispersion of naproxen using polyvinylpyrrolidone K30: preparation, characterization and in-vitro evaluation. Int J Pharm Pharm Sci. 2022;14(4):51-58.

30. World Health Organization. International Pharmacopoeia: Biopharmaceutics Classification System for Immediate-release Solid Oral Dosage Forms. Geneva: WHO Press; 2023.

31. Craig DQ. The mechanisms of drug release from solid dispersions in water-soluble polymers. Int J Pharm. 2002;231(2):131-144.

32. Baghel S, Cathcart H, O'Reilly NJ. Polymeric amorphous solid dispersions: a review of amorphization, crystallization, stabilization, solid-state characterization, and aqueous solubilization of biopharmaceutical classification system class II drugs. J Pharm Sci. 2016;105(9):2527-2544.

33. Van den Mooter G. The use of amorphous solid dispersions: a formulation strategy to overcome poor solubility and dissolution rate. Drug Discov Today Technol. 2012;9(2):e79-e85.

34. Singh A, Van den Mooter G. Spray drying formulation of amorphous solid dispersions. Adv Drug Deliv Rev. 2016;100:27-50.

35. Kambayashi A, Loftsson T, Jansook P. Cyclodextrin-based solid dispersion: ternary complexation of hydrocortisone. Int J Pharm. 2020;590:119903.

36. Yu L, Reutzel-Edens SM, Mitchell CA. Crystallization and polymorphism of conformationally flexible molecules: problems, patterns, and strategies. Org Process Res Dev. 2000;4(5):396-402.

37. Janssens S, Van den Mooter G. Review: physical chemistry of solid dispersions. J Pharm Pharmacol. 2009;61(12):1571-1586.

38. Bhatt P, Agrawal SS, Bhatt DL. Natural gums in solid dispersion: a review. World J Pharm Pharm Sci. 2020;9(6):1286-1300.

39. Hasnain MS, Nayak AK. Natural polysaccharides as carriers for drug solubility enhancement: current status and future directions. Int J Pharm. 2018;549(1-2):349-365.

40. Madgulkar AR, Bhalekar MR, Padalkar AN. In-vitro and in-vivo studies on solid dispersion of poorly soluble drug: guar gum as a carrier. Indian J Pharm Sci. 2009;71(1):21-26.

41. Sinha VR, Kumria R. Polysaccharides in colon-specific drug delivery. Int J Pharm. 2001;224(1-2):19-38.

42. Bhatt PP, Bhattacharya SS, Kumbhar PS, Bora V. Pharmaceutical applications of guar gum-based systems: a review. Polym Bull. 2021;78(5):2571-2596.

43. Desai J, Alexander K, Riga A. Characterization of polymeric dispersions of dimenhydrinate in ethyl cellulose for controlled release. Int J Pharm. 2006;308(1-2):115-123.

44. García-Ochoa F, Santos VE, Casas JA, Gómez E. Xanthan gum: production, recovery, and properties. Biotechnol Adv. 2000;18(7):549-579.

45. Sworn G. Xanthan gum. In: Phillips GO, Williams PA, editors. Handbook of Hydrocolloids. 2nd ed. Cambridge: Woodhead Publishing; 2009. p. 186-203.

46. Verma S, Nagpal K, Singh SK, Mishra DN. Xanthan gum-based solid dispersions for poorly soluble drugs: preparation, characterization, and in-vitro evaluation. Drug Dev Ind Pharm. 2024;50(3):214-228.

47. Verbeken D, Dierckx S, Dewettinck K. Exudate gums: occurrence, production, and applications. Appl Microbiol Biotechnol. 2003;63(1):10-21.

48. Williams PA, Phillips GO. Gum arabic. In: Phillips GO, Williams PA, editors. Handbook of Hydrocolloids. 2nd ed. Cambridge: Woodhead Publishing; 2009. p. 252-273.

49. Reddy KR, Murthy TE, Shankar NS. Evaluation of gum acacia as carrier in solid dispersion of naproxen: physicochemical characterization and dissolution studies. J Drug Deliv Sci Technol. 2024;91:105231.

50. Verma A, Sharma A, Singh P. Solid dispersions of naproxen: hydroxypropyl methylcellulose versus HP-β-cyclodextrin - a comparative study. AAPS PharmSciTech. 2024;25(2):56.

51. Chaudhary A, Prasad PS, Kasliwal N. Effect of preparation method on properties of naproxen-Poloxamer 407 solid dispersions. J Pharm Investig. 2022;52(4):495-508.

52. Kaur G, Kaur R. Comparative evaluation of Soluplus, PVP K90 and HPMC as solid dispersion carriers for naproxen. Asian J Pharm. 2023;17(3):204-214.

53. Ali A, Khan T, Sohail M. Solid dispersion approaches for NSAID bioavailability enhancement: a systematic review 2018-2023. Drug Des Devel Ther. 2023;17:2143-2162.

54. Kumar R, Sharma S, Mehta A. Natural polymer-based solid dispersions: current status and future prospects. J Drug Deliv Sci Technol. 2026;95:105650.

55. Mehta R, Singh P, Gupta A. Modified natural gum carriers in solid dispersions: influence on recrystallization behaviour of BCS Class II drugs. Carbohydr Polym. 2026;328:121716.

56. Patel NK, Chotai NP, Patel JK, Zia H. Comparison of in vitro dissolution profiles of marketed naproxen formulations using model-independent and model-dependent methods. Dissolution Technol. 2009;16(4):41-47.

57. Indian Pharmacopoeia Commission. Indian Pharmacopoeia, Vol. II. Ghaziabad: IPC; 2022. p. 2408-2410.

58. United States Pharmacopeia and National Formulary (USP 46-NF 41). Rockville, MD: United States Pharmacopeial Convention; 2023.

59. European Pharmacopoeia, 11th ed. Strasbourg: Council of Europe; 2023.

60. ICH Harmonised Tripartite Guideline. Stability Testing of New Drug Substances and Products Q1A(R2). International Conference on Harmonisation; 2003.

61. Huang Y, Dai W-G. Fundamental aspects of solid dispersion technology for poorly soluble drugs. Acta Pharm Sin B. 2014;4(1):18-25.

62. Duong TT, Tran PH, Tran TT. The roles of polymer concentration and type on the dissolution enhancement of poorly water-soluble drugs in solid dispersions. Pharmaceutics. 2022;14(2):452.

63. Kolter K, Karl M, Gryczke A. Hot-Melt Extrusion with BASF Pharma Polymers: Extrusion Compendium. 2nd ed. Ludwigshafen: BASF SE; 2012.

64. Gupta MK, Goldman D, Bogner RH, Tseng YC. Enhanced drug dissolution and bulk properties of solid dispersions granulated with a surface adsorbent. Pharm Dev Technol. 2001;6(4):563-572.

65. Mosharraf M, Nyström C. The effect of particle size and shape on the surface specific dissolution rate of microsized practically insoluble drugs. Int J Pharm. 1995;122(1-2):35-47.

66. Serajuddin AT. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J Pharm Sci. 1999;88(10):1058-1066.

67. Corrigan OI. Thermal analysis of spray dried products. Thermochim Acta. 1995;248:245-258.

Downloads

Published

2026-09-21

Issue

Section

Original Research Articles

Similar Articles

You may also start an advanced similarity search for this article.